Global Melanoma Therapeutics Market, By Type (Superficial Spreading Melanoma, Nodular Melanoma, Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Amelanotic Melanoma, Others), Stages (Stage 0, Stage 1, Stage 2, Stage 3, Stage 4, Others), Therapy (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Melanoma Therapeutics Market Analysis and Size
As per the records of WHO, around 132,000 cases of skin cancer occur each year. Furthermore, a 10% decrease in ozone levels is projected to lead to an increase of 4,500 skin cancer cases globally. The incidence of skin allergies, melanoma, and other skin cancers in highly developing countries is high, that serves as an opportunity for drug companies to gain a larger share in these regions. Genes and UV radiations are majorly responsible for causing melanoma.
Data Bridge Market Research analyses a growth rate in the melanoma therapeutics market in the forecast period 2023-2030. The expected CAGR of melanoma therapeutics market is tend to be around 16.30% in the mentioned forecast period. The market was valued at USD 3.45 billion in 2022, and it would grow upto USD 11.55 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Melanoma Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Superficial Spreading Melanoma, Nodular Melanoma, Lentigo Maligna Melanoma, Acral Lentiginous Melanoma, Amelanotic Melanoma, Others), Stages (Stage 0, Stage 1, Stage 2, Stage 3, Stage 4, Others), Therapy (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A. (France), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switzerland), Genentech, Inc (U.S.), AstraZeneca (U.K.), DAIICHI SANKYO COMPANY, LIMITED (Japan), AB Science (France), AgonOX (U.S.), Eisai Co., Ltd (Japan), Pfizer, Inc.(U.S.)
|
|
Market Opportunities
|
|
Market Definition
Melanoma is the most hazardous type of skin cancer that develops in the melanocytes cells which produce melanin. Melanoma can also produce in the eyes and most rarely inside the body such as nose and throat. There are various risk factors for melanoma, including overexposure to the sun, a family history of melanoma, and having fair skin, among others. Melanoma is considered to be the deadliest of these three types of skin cancer.
Global Melanoma Therapeutics Market
Drivers
- Increasing Demand of Radiation Therapy
The radiation therapy is projected to show steady growth during the forecast period due to the growing number of advanced melanoma cases and the increasing use of radiation as an adjuvant therapy post-surgery. Radiation therapy is often used as a primary treatment. It is only administered to stage 4 patients who cannot be treated with surgery.
- Increase in Skin Cancer
According to records of WHO, about 132,000 cases of skin cancer occur each year. Additionally, a 10% reduction in ozone levels is projected to lead to an increase of 4,500 skin cancer cases worldwide. The incidence of skin allergies, melanoma, and other skin cancers in developing countries is more, that serves as an opportunity for many drug companies to gain a greater share in these regions. This is estimated to increase the demand for these drugs during the forecast period.
Opportunities
- Growing Regulatory Approvals By Authorizations
The high emphasis and increasing investment in highly developing efficient treatment options are most likely to significantly impact the market growth. Treatment recommendations depend on several factors, and the increasing number of regulatory approvals has considerably impacted the market growth. For instance, in 2021, Binimetinib, Braftovi, Aldesleukin, Cobimetinib Fumarate, Dabrafenib Mesylate, Cotellic were some of the approved drugs that are used for the treatment of cancer by FDA. The significance of major key players on introducing several innovative treatment options and drugs will support the market growth in the upcoming years.
- Development of new Biologics
The major market players in the U.S., Europe, and Asia Pacific are focusing on developing several new biologics for the treatment of melanoma. For instance, in March 2017, Take a Novel Challenge for Drug Discovery (TaNeDS) was introduced by Daiichi Sankyo Company Limited, a collaborative project aimed at facilitating new drug development through various collaborations. In addition to this, it has a strategic research partnership with AgonOX, Inc. to explore innovative immunotherapy treatments for the market.
Restraints/Challenges
- Unavailability of Appropriate Treatments
To treat many different types of cancers, there are times when all treatments are not available, particularly in underdeveloped countries. Severe patients need to be treated with many advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Therefore, it impedes the market growth.
- Increasing Rate of Patent Expiration Drugs
There are several drugs that lose expiry and it takes much time to get back the patent. Branded drugs are anticipated to lose their market share during the forecast period because of the patent expiration of notable brands such as Yervoy and Imlygic. Imlygic is projected to lose its patent protection in 2021, which will result in reduced revenue for Amgen, Inc. Likewise, Yervoy is estimated to lose its patent exclusivity in the U.S. in 2022 and Europe in 2020.
This melanoma therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the melanoma therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Melanoma Therapeutics Market
The pandemic has considerably affected various diagnostic methods due to numerous restrictions and risk exposure of comorbidity patients. A drastic reduction in skin biopsies was seen early in the COVID-19 pandemic, which unreasonably affected the elderly, females, and certain geographic regions. Though, government organizations have made efforts to contain the situation in the post-pandemic era.
Recent Development:
In 2020, AstraZeneca and Merck & Co. got FDA approval of the drug selumetinib to treat neurofibromatosis type 1, or NF1, a rare and characteristically inherited disease which causes tumors to grow inside nerve sheaths. Additionally, Merck joined AstraZeneca in developing and commercializing Koselugo as part of a deal that included the ovarian cancer drug Lynparza.
Global Melanoma Therapeutics Market Scope
The melanoma therapeutics market is segmented on the basis of type, stages, chemotherapy, drug type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Superficial Spreading Melanoma
- Nodular Melanoma
- Lentigo Maligna Melanoma
- Acral Lentiginous Melanoma
- Amelanotic Melanoma
- Others
Stages
- Stage 0
- Stage 1
- Stage 2
- Stage 3
- Stage 4
- Others
Chemotherapy
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Immunotherapy
- Others
Drug Type
- Branded
- Generic
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Melanoma Therapeutics Market Regional Analysis/Insights
The melanoma therapeutics market is analyzed and market size insights and trends are provided by ype, stages, chemotherapy, drug type, distribution channel and end-user as referenced above.
The major countries covered in the melanoma therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for melanoma therapeutics market throughout the forecasted period due to the constant rise in skin cancer and increased demand for cost-efficient therapeutics.
North America dominates the market due to the presence of high healthcare expenditure and favorable reimbursement policies for treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Melanoma Therapeutics Market Share Analysis
The melanoma therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to melanoma therapeutics market.
Key players operating in the melanoma therapeutics market include:
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Limited (India)
- Sanofi S.A. ( France)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Amgen Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Novartis AG (Switzerland)
- Genentech, Inc (U.S.)
- AstraZeneca (U.K.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- AB Science (France)
- AgonOX (U.S.)
- Eisai Co., Ltd (Japan)
- Pfizer, Inc.(U.S.)
SKU-